PARP1 and ovarian carcinoma: Currently, four PARP inhibitors (PARPi), Olaparib, Rucaparib, Niraparib, and Talazoparib have been approved for the treatment of breast, pancreatic, prostate, primary peritoneal and ovarian cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [134, 135].